Trading of the combined Pfizer/Pharmacia company began April 16 on theNew York Stock Exchange under Pfizer's existing ticker code' PFE. By market capitalization, the newly-merged entity is now the third-largest company in the world.
Discussing the benefits of the merger, executive vice president David Shedlarz said: "as we move to rapidly integrate Pharmacia into our operations, we will be in a position to capture the revenue and expense synergies between the two companies, focus our assets and efforts intensively on our core businesses, and continue to fund long-term R&D at a rate that will sustain our leadership far into the future." Pfizer expects to achieve merger-related cost savings of around $2.5 billion by 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze